Harmony Biosciences Holdings Inc (NAS:HRMY)
$ 34.2 -0.52 (-1.5%) Market Cap: 1.95 Bil Enterprise Value: 1.75 Bil PE Ratio: 16.21 PB Ratio: 3.27 GF Score: 65/100

Harmony Biosciences Holdings Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 09:00PM GMT
Release Date Price: $36.23 (+2.72%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Great. Good afternoon, everyone, and thanks to the team from Harmony. We have Jeff Dayno here, CEO recently; as well as Sandip Kapadia, who's the CFO.

And maybe we'll just start to level set, could you provide a brief overview of the company, perhaps with a particular focus on what you view as key value drivers over the next 12 to 24 months?

Jeffrey M. Dayno
Harmony Biosciences Holdings, Inc. - President, CEO & Director

Yes. Sure, Corinne. So first of all, on behalf of the Harmony team, thank you for the invitation to participate in the conference this year. So I think Harmony, basically, we are, as a little overview and background, a commercial-stage pharmaceutical company founded in 2017. We are now profitable and cash generating. And I think we're focused on developing and delivering innovative therapies for patients living with rare neurologic diseases.

Our first product, WAKIX, that is a first-in-class molecule with a novel mechanism of action, was approved in 2019

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot